Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages

  • Pfizer Inc PFE and BioNTech SE BNTX announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-tailored bivalent COVID-19 vaccine against newer Omicron sublineages.
  • These data, posted on the preprint server bioRxiv, indicate that the companies' bivalent vaccine elicits a greater increase in neutralizing antibody titers than the companies' original COVID-19 vaccine against these emerging Omicron sublineages. 
  • Related: Pfizer, BioNTech Start Work On Next-Gen COVID-19 Vaccine Candidate For Broader Protection.
  • One month after a 30-µg booster (fourth) dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibodies against BA.4.6 increased 11.1-fold, neutralizing antibodies against BA.2.75.2, BQ.1.1, and XBB.1 increased by 6.7-fold, 8.7-fold, and 4.8-fold, respectively. 
  • By comparison, the neutralizing antibody titers against BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 following the original shot's booster dose increased 2.3-fold, 2.1-fold, 1.8-fold, and 1.5-fold, respectively. 
  • Overall, the bivalent booster generated a greater increase in neutralizing antibodies against emerging Omicron sublineages than the original Pfizer-BioNTech COVID-19 vaccine.
  • Price Action: PFE shares are down 0.08% at $48.29, and BNTX stock is up 0.31% at $166.78 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!